F2RL1 and cancer: Although direct studies on statins’ effects on PAR signalling are scarce, emerging evidence, particularly on PAR-2, suggests statins may attenuate this pathway, contributing to their therapeutic effects across diabetes, cancer, and osteoarthritis.